Foresite Capital Management IV, LLC
Follow13F filer, CIK 1704132, WEST HOLLYWOOD, CA
Foresite Capital Management IV, LLC reported $252,030,239 across 6 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16.
Accepted , ingested 13F-HR 0001104659-26-128376
- Period
- 2026-09-30
- Reported value
- $252M
- Holdings
- 6
- Top 10 weight
- 100%
- New
- 1
- Sold out
- 1
Part of the filer group Foresite Capital Management VI LLC
Foresite Capital Management VI LLCForesite Capital Management V, LLC
- Foresite Capital Management VI LLC
- Foresite Capital Management V, LLC
- Foresite Public & Crossover Opportunities Fund I, L.P.
- Foresite Public & Crossover Opportunities Management I, LLC
- James B. Tananbaum
- Foresite Capital Fund VI LP
Stakes and trades reported after 2026-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- IRLA QUINCE THERAPEUTICS INC: 13G 652,039 shares, 6% of the class, 13G filed 2026-10-14, 0001104659-26-115859Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| VCYTnew | +200,000 | $9.21M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| CRNXexited | -150,000 | -$5.61M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001104659-26-128376, largest first. % of portfolio is the value over $252,030,239, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| PHVSPHARVARIS N V | 4,778,581 | $152M | 60.14% | 0 | Timeline | ||
| CYTKCYTOKINETICS INC | 714,695 | $47.1M | 18.69% | 0 | Timeline | ||
| RLAYRELAY THERAPEUTICS INC | 1,250,000 | $22.6M | 8.95% | 0 | Timeline | ||
| EIKNEIKON THERAPEUTICS INC | 1,943,682 | $15.6M | 6.2% | 0 | Timeline | ||
| VCYTVERACYTE INC | 200,000 | $9.21M | 3.65% | new | Timeline | ||
| XENEXENON PHARMACEUTICALS INC | 160,000 | $5.95M | 2.36% | 0 | Timeline |
Sold out in Q3 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| CRNXCRINETICS PHARMACEUTICALS IN | 150,000 | $5.61M | shares |
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001104659-26-128376 | base | 2026-11-16 |